<DOC>
	<DOCNO>NCT03104725</DOCNO>
	<brief_summary>Objective : This study test whether N-acetylcysteine ( NAC ) inhibit spontaneous oxidation central neural dopamine indicate cerebrospinal fluid ( CSF ) concentration 5-S-cysteinyl-dopamine ( Cys-DA ) patient Parkinson disease ( PD ) . Study population : The study population comprise 35 patient early ( 5 year diagnosis ) , mild , levodopa-untreated PD . The patient inhibitor monoamine oxidase ( MAO ) prescribe disease . Design : The study one group , pretest-posttest design . Each patient undergo lumbar puncture ( LP ) inpatient NIH Clinical Center obtain cerebrospinal fluid ( CSF ) assay Cys-DA , 3,4-dihydroxyphenylacetic acid ( DOPAC ) , related biochemicals . The second LP do patient take least 5 dos NAC ( 2 gram orally twice per day ) . The LP take place 2 hour last NAC dose . Outcome measure : The main outcome measure CSF concentration Cys-DA . Other outcome measure level catecholamine-related neurochemical index oxidative stress . Depending result , exploratory study may do involve NAC 1 gram orally twice per day .</brief_summary>
	<brief_title>Does N-Acetylcysteine Decrease Spontaneous Oxidation Central Neural Dopamine Parkinson 's Disease ?</brief_title>
	<detailed_description>Objective : This study test whether N-acetylcysteine ( NAC ) inhibit spontaneous oxidation central neural dopamine indicate cerebrospinal fluid ( CSF ) concentration 5-S-cysteinyl-dopamine ( Cys-DA ) patient Parkinson disease ( PD ) . Study population : The study population comprise 35 patient early ( less equal 5 year diagnosis ) , mild , levodopa-untreated PD . The patient inhibitor monoamine oxidase ( MAO ) prescribe disease . Design : The study one group , pretest-posttest design . Each patient undergo lumbar puncture ( LP ) inpatient NIH Clinical Center obtain cerebrospinal fluid ( CSF ) assay Cys-DA , 3,4-dihydroxyphenylacetic acid ( DOPAC ) , related biochemicals . The second LP do patient take least 5 dos NAC ( 2 gram orally twice per day ) . The LP take place 2 hour last NAC dose . Outcome measure : The main outcome measure CSF concentration Cys-DA . Other outcome measure level catecholamine-related neurochemical index oxidative stress . Depending result , exploratory study may do involve NAC 1 gram orally twice per day .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>INCLUSION CRITERIA : PD diagnose within past 5 year Taking monoamine oxidase ( MAO ) inhibitor Able provide consent At least18 year old EXCLUSION CRITERIA : Taking levodopa form Known allergy NAC Already take antioxidant dietary supplement ( e.g. , Olive Leaf Extract , MitoQ ) A condition would increase risk lumbar puncture ( e.g. , symptomatic spinal stenosis myoclonus ) History postspinal headache require treatment blood patch On prescribed anticoagulant ( e.g. , Coumadin , Plavix ) Pregnant breastfeed History alcohol drug abuse Any medical condition thatcould put subject increase risk . Potential participant exclude evidence bone marrow , liver , kidney failure base abnormal screen lab result . On medication could interfere scientific result . An example exclusionary drug catecholOmethyltransferase inhibitor entacapone . Tricyclic antidepressant another type exclusionary drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 24, 2017</verification_date>
	<keyword>5-S-Cysteinyldopamine</keyword>
	<keyword>Cerebrospinal Fluid</keyword>
	<keyword>PARKINSONS DISEASE</keyword>
	<keyword>MONOAMINE OXIDASE INHIBITOR</keyword>
</DOC>